Efficacy of a new fluoroquinolone, JNJ-Q2, in murine models of Staphylococcus aureus and Streptococcus pneumoniae skin, respiratory, and systemic infections

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 12, 2011, Pages 5522-5528

  Fernandez, Jeffrey ^a   Hilliard, Jamese J ^a,b   Morrow, Brian J ^a   Melton, John L ^a   Flamm, Robert K ^a,c   Barron, Alfred M ^a   Lynch, A Simon ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b MEDIMMUNE   (United States)

^c JMI LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GEMIFLOXACIN; JNJ Q2; LINEZOLID; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; INFECTION; LOWER RESPIRATORY TRACT INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MOUSE; NONHUMAN; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; SEPTICEMIA; SKIN INFECTION; STAPHYLOCOCCAL SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; SYSTEMIC INFECTION; TITRIMETRY;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTEREMIA; COMMUNITY-ACQUIRED INFECTIONS; DISEASE MODELS, ANIMAL; FEMALE; FLUOROQUINOLONES; HUMANS; METHICILLIN; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; RESPIRATORY TRACT INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 81555206710     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00471-11     Document Type: Article

References (33)

1. Adam, H. J., D. J. Hoban, A. S. Gin, and G. G. Zhanel. 2009. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006. Int. J. Antimicrob. Agents 34:82-85.
2. Almer, L. S., J. B. Hoffrage, E. L. Keller, R. K. Flamm, and V. D. Shortridge. 2004. In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against gram-positive and gram-negative organisms. Antimicrob. Agents Chemother. 48:2771-2777. (Pubitemid 38823464)
3. An, M. M., et al. 2010. Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials. Int. J. Antimicrob. Agents 36:58-65.
4. Ardanuy, C., et al. 2009. Emergence of a multidrug-resistant clone (ST320) among invasive serotype 19A pneumococci in Spain. J. Antimicrob. Chemother. 64:507-510.
5. Bhagwat, S. S., P. McGhee, K. Kosowska-Shick, M. V. Patel, and P. C. Appelbaum. 2009. In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types. Antimicrob. Agents Chemother. 53:811-813.
6. Blumberg, H. M., D. Rimland, D. J. Carroll, P. Terry, and I. K. Wachsmuth. 1991. Rapid development of ciprofloxacin resistance in methicillin-susceptible and-resistant Staphylococcus aureus. J. Infect. Dis. 163:1279-1285.
7. Bunce, C., L. Wheeler, G. Reed, J. Musser, and N. Barg. 1992. Murine model of cutaneous infection with gram-positive cocci. Infect. Immun. 60:2636-2640.
8. Cagni, A., C. Chuard, P. E. Vaudaux, J. Schrenzel, and D. P. Lew. 1995. Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 39:1655-1660.
9. CLSI. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-7th ed., vol. 29. CLSI document M07-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Dagan, R., N. Givon-Lavi, E. Leibovitz, D. Greenberg, and N. Porat. 2009. Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. J. Infect. Dis. 199:776-785.
11. Davies, T. A., et al. 2008. Effects of the 7-valent pneumococcal conjugate vaccine on U.S. levofloxacin-resistant Streptococcus pneumoniae. Microb. Drug Resist. 14:187-196.
12. Davies, T. A., Y. C. Yee, R. Goldschmidt, D. F. Sahm, and A. T. Evangelista. 2008. Decline in the prevalence of pandemic clones Spain23F-1 and Spain9V-3 among US fluoroquinolone-resistant Streptococcus pneumoniae TRUST surveillance isolates since 2001. Postgrad. Med. 120:39-45.
13. Fernandez, J., et al. 2010. In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 54:116-125.
14. Fernandez, J., et al. 2010. Efficacy of a new fluoroquinolone (FQ) JNJ-Q2 in murine models of Staphylococcus aureus and Streptococcus pneumoniae infection, abstr. F1-2093. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., Boston, MA.
15. Fritsche, T. R., H. S. Sader, and R. N. Jones. 2007. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004). Diagn. Microbiol. Infect. Dis. 58:19-26. (Pubitemid 46694276)
16. Hilliard, J. J., et al. 2009. In vivo activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457. Antimicrob. Agents Chemother. 53:2028-2033.
17. Hoshino, K., et al. 2008. In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone. Antimicrob. Agents Chemother. 52:65-76.
18. Jones, R. N., R. E. Mendes, and H. S. Sader. 2010. Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study. J. Antimicrob. Chemother. 65:17-31.
19. Klevens, R. M., et al. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771. (Pubitemid 47598444)
20. Li, M., et al. 2009. Evolution of virulence in epidemic community-associated methicillin-resistant Staphylococcus aureus. Proc. Natl. Acad. Sci. U. S. A. 106:5883-5888.
21. Little, R. C., G. A. Milliken, W. W. Stroup, R. D. Wolfinger, and O. Schabenbgerger. 2006. SAS for mixed models. SAS Institute, Inc., Cary, NC.
22. Liu, X. G., and R. C. Li. 2001. Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. J. Chemother. 13:563-568. (Pubitemid 33001121)
23. Miyazaki, E., M. Miyazaki, J. M. Chen, R. E. Chaisson, and W. R. Bishai. 1999. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob. Agents Chemother. 43:86-89.
24. Morrow, B. J., et al. 2010. In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone. Antimicrob. Agents Chemother. 54:1955-1964.
25. Morrow, B. J., et al. 2011. Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2. Antimicrob. Agents Chemother. 55:5512-5521.
26. Owens, R. C., Jr., and P. G. Ambrose. 2002. Pharmacodynamics of quinolones, p. 155-176. In C. H. Nightingale, T. Murakawa, and P. G. Ambrose (ed.), Antimicrobial pharmacodynamics in theory and clinical practice. Marcel Dekker Inc., New York, NY.
27. Patel, M. V., et al. 2004. Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models. Antimicrob. Agents Chemother. 48:4754-4761. (Pubitemid 39577681)
28. Pishchany, G., et al. 2010. Specificity for human hemoglobin enhances Staphylococcus aureus infection. Cell Host Microbe 8:544-550.
29. SAS Institute. 2008. The logistic procedure; SAS/STAT 9.2 user's guide. SAS Institute, Inc., Cary, NC.
30. Siefert, H. M., et al. 1999. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. J. Antimicrob. Chemother. 43:69-76.
31. Trong, H. N. G., A.-L. Prunier, and R. Leclercq. 2005. Hypermutable and fluoroquinolone-resistant clinical isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 49:2098-2101. (Pubitemid 40631630)
32. Watanabe, S., T. Ito, and K. Hiramatsu. 2007. Susceptibilities of healthcareand community-associated methicillin-resistant staphylococci to the novel des-F(6)-quinolone DX-619. J. Antimicrob. Chemother. 60:1384-1387. (Pubitemid 350168338)
33. Westfall, P. H. T., R. D. D. Rom, R. D. Wolfinger, and Y. Hochberg. 1999. Multiple comparisons and multiple tests using the SASTM system. SAS Institute Inc., Cary, NC.